Knee cartilage repair versus stem cell therapyEstablished cartilage repair using autologous chondrocytes shows 10–17 year durability for focal knee defects; mesenchymal stem cell therapies have not been tested in large-scale trials against them.Established cartilage repair using autologous chondrocytes shows 10–17 year durability for focal knee defects; mesenchymal stem cell therapies have not been tested in large-scale trials against them.
ChondroFiller injection versus knee replacement for focal defectsChondroFiller, a gelling collagen scaffold that recruits the patient's own cells to repair cartilage, suits isolated focal defects; knee replacement addresses widespread multi-compartment osteoarthritis.ChondroFiller, a gelling collagen scaffold that recruits the patient's own cells to repair cartilage, suits isolated focal defects; knee replacement addresses widespread multi-compartment osteoarthritis.
Knee cartilage damage left untreated and when repair helpsCartilage lacks blood vessels, nerve fibres, and lymph channels, so repair cells cannot reach injuries and pain does not warn of damage, allowing lesions to expand silently until they become clinically serious.Cartilage lacks blood vessels, nerve fibres, and lymph channels, so repair cells cannot reach injuries and pain does not warn of damage, allowing lesions to expand silently until they become clinically serious.
ChondroFiller™ durability compared with ArthrosamidChondroFiller™ recruits the patient's own progenitor cells to build new cartilage tissue within a collagen scaffold. Three-year published follow-up shows mean IKDC scores of 80 — a 32.4-point improvement from baseline — with durability reported to extend beyond five years.ChondroFiller™ recruits the patient's own progenitor cells to build new cartilage tissue within a collagen scaffold. Three-year published follow-up shows mean IKDC scores of 80 — a 32.4-point improvement from baseline — with durability reported to extend beyond five years.
ChondroFiller injection cost in the UKChondroFiller injection costs £3,000–£9,800 depending on cartilage defect size; the NHS does not fund it, and quoted prices bundle assessment, imaging, injection, and six-week follow-up.ChondroFiller injection costs £3,000–£9,800 depending on cartilage defect size; the NHS does not fund it, and quoted prices bundle assessment, imaging, injection, and six-week follow-up.
ChondroFiller injection for knee cartilage defectsThe injected collagen scaffold gels in place and recruits the body's own progenitor cells to repair the cartilage defect without surgery or general anaesthetic. Functional scores improve from 48 to 80 on the IKDC scale over three years in independent European cohorts, with most of that improvement within six months.The injected collagen scaffold gels in place and recruits the body's own progenitor cells to repair the cartilage defect without surgery or general anaesthetic. Functional scores improve from 48 to 80 on the IKDC scale over three years in independent European cohorts, with most of that improvement within six months.
Who qualifies for MACI knee surgery?Patients aged 18–55 with deep focal cartilage damage (Grade III-IV, >2 cm²) qualify for MACI if their knees are structurally sound—stable ligaments, correct alignment, no generalised osteoarthritis—and conservative treatment has failed. The procedure is two-stage, with extended rehabilitation required.Patients aged 18–55 with deep focal cartilage damage (Grade III-IV, >2 cm²) qualify for MACI if their knees are structurally sound—stable ligaments, correct alignment, no generalised osteoarthritis—and conservative treatment has failed. The procedure is two-stage, with extended rehabilitation required.
Cartilage specialist or general orthopaedic surgeon for a knee defectKnee cartilage repair without correcting underlying malalignment results in reoperation in 47.4% of cases, versus 17.3% when alignment is corrected simultaneously — a surgical integration that general orthopaedic surgeons often omit from initial assessment and planning.Knee cartilage repair without correcting underlying malalignment results in reoperation in 47.4% of cases, versus 17.3% when alignment is corrected simultaneously — a surgical integration that general orthopaedic surgeons often omit from initial assessment and planning.
Choosing between ACI and MACI for cartilage repairMACI cartilage grafts show 90% fill at two years but decline to 49% by ten years; 73% become fibrocartilage rather than the hyaline cartilage needed for durability.MACI cartilage grafts show 90% fill at two years but decline to 49% by ten years; 73% become fibrocartilage rather than the hyaline cartilage needed for durability.
ChondroFiller injection versus cartilage surgeryChondroFiller injection achieves 30 IKDC improvement with 3–8% reoperation and 0% complications; microfracture carries 41% reoperation rates with declining long-term outcomes; ACI/MACI matches functional gains but brings 17% complications and 37% reoperation.ChondroFiller injection achieves 30 IKDC improvement with 3–8% reoperation and 0% complications; microfracture carries 41% reoperation rates with declining long-term outcomes; ACI/MACI matches functional gains but brings 17% complications and 37% reoperation.
What separates ChondroFiller from Liquid CartilageChondroFiller is a single collagen scaffold delivered two ways: as an outpatient injection alone, or combined with patient-derived cells under the clinical brand Liquid Cartilage™. Naming overlap at clinics obscures which is being offered.ChondroFiller is a single collagen scaffold delivered two ways: as an outpatient injection alone, or combined with patient-derived cells under the clinical brand Liquid Cartilage™. Naming overlap at clinics obscures which is being offered.
ChondroFiller injection safety and the questions to askChondroFiller shows a near-zero complication rate across published trials and over 19,000 post-market cases; fibrous tissue forms only when the scaffold is overfilled, making precise dose determination from pre-procedure MRI the key safeguard.ChondroFiller shows a near-zero complication rate across published trials and over 19,000 post-market cases; fibrous tissue forms only when the scaffold is overfilled, making precise dose determination from pre-procedure MRI the key safeguard.